Evidence map›Paper›PMID 35813028›Full record

ArticleBio-protocol2022

CRISPR/Cas9 Gene Editing of HeLa Cells to Tag Proteins with mNeonGreen.

Sachin Surve, Alexander Sorkin

Abstract read
In one paragraph

Article in Bio-protocol, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Sachin SurveDepartment of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Alexander SorkinDepartment of Cell Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Funding

PATHOGENESIS OF CANCER--ROLE OF EGF RECEPTOR ENDOCYTOSISR01CA089151 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SORKIN, ALEXANDER D · 2001 to 2023
$6.9M
Signaling by the EGF Receptor from EndosomesR01GM124186 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SORKIN, ALEXANDER D · 2017 to 2021
$1.6M
NCI NIH HHS R01 CA089151NIGMS NIH HHS R01 GM124186
6 · The paper itself

Abstract

Subcellular localization dynamics of proteins involved in signal transduction processes is crucial in determining the signaling outcome. However, there is very limited information about the localization of endogenous signaling proteins in living cells. For example, biochemical mechanisms underlying the signaling pathway from epidermal growth factor (EGF) receptor (EGFR) to RAS-RAF and ERK1/2/MAPK are well understood, whereas the operational domains of this pathway in the cell remain poorly characterized. Tagging of endogenous components of signaling pathways with fluorescent proteins allows more accurate characterization of their intracellular dynamics at their native expression levels controlled by endogenous regulatory mechanisms, thus avoiding possible tainting effects of overexpression and mistargeting. In this study, we describe methodological approaches to label components of the EGFR-RAS-MAPK pathway, such as Grb2, KRAS, and NRAS, with the fluorescent protein mNeonGreen (mNG) using CRISPR/Cas9 gene-editing, as well as generation of homozygous single-cell clones of the edited target protein.

Indexed as

CRISPR-Cas9EGF receptorKRASmNeonGreenNRAS

Identifiers

PMID35813028
PMCPMC9183963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.